At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 8, 2026 at 06:30 ET
Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six months in its company-sponsored trial, and FDA alignment on a single registrational Phase 3 trial expected to start H2 2026. The data supports AlloNK's potential as an off-the-shelf deep B-cell depleting therapy with a favorable outpatient tolerability profile, de-risking the path to a BLA submission in 2029.
- 71% ACR50 response at six months in company-sponsored Phase 2a basket trial (5 of 7 patients) in refractory RA.
- FDA alignment on a single registrational Phase 3 trial for AlloNK in refractory RA, with ACR50 at six months as primary endpoint.
- Phase 3 trial expected to enroll ~150 patients, randomized 2:1 AlloNK+rituximab vs rituximab alone, with crossover option.
- No CRS, ICANS, or treatment discontinuations observed in autoimmune patients; tolerability supports outpatient community administration.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access